

**The CANCER THERAPEUTICS TRAINING PROGRAM LECTURE SERIES (CHEM239) 2015 – 2016**  
**Tuesdays 12:00 to 1:00 PM      Lunch is available at 11:45 AM for those attending the lecture**

<b>Date</b>	<b>Speaker</b>	<b>Affiliation</b>	<b>Title</b>	<b>Location</b>
9/22/15	<b>Stephen Howell, MD</b>	Moores UCSD Cancer Center	<b>Introduction to Oncology Drug Development</b>	Comer Commons
9/29/15	<b>Kristen M. Hege, MD</b>	<b>Celgene Corporation</b>	<b>Next Generation Therapeutics Targeting the mTOR Pathway (acceptance confirmed 7/15/15)</b>	Comer Commons
10/6/15	<b>Lyudmila Bazhenova, MD</b>	Moores UCSD Cancer Center	<b>Chomping our way through the pie, updates in lung cancer management.</b>	Comer Commons
10/13/15	<b>Steve Schoenberger, PhD</b>	Moores UCSD Cancer Center	<b>Translational cancer immunotherapy for solid tumors</b>	Comer Commons
10/20/15	<b>Tannishtha Reya, PhD</b>	Moores UCSD Cancer Center	<b>New models for imaging cancer stem cells and therapy resistance in real time</b>	Comer Commons
10/27/15	<b>Chris Klebanoff, MD</b>	NCI	<b>Quorum sensing-like behavior among T cells: development of quorum therapeutics for adoptive cell therapy</b>	Comer Commons
11/03/15	<b>Alfredo A. Molinolo MD, PhD</b>	Moores UCSD Cancer Center	<b>Head and Neck Cancer - All roads lead to mTOR</b>	Comer Commons
11/17/15	<b>Trey Ideker, PhD</b>	Moores UCSD Cancer Center	Cancer Systems Biology	Comer Commons
11/24/15	<b>Bill Fenical, PhD (Ezra to host)</b>	Moores UCSD Cancer Center	<b>Natural Products, the Foundation of Cancer Drug Discovery</b>	Comer Commons
12/1/15	<b>Jay Srirangam</b>	Pfizer	<b>Overview of Pharma R&amp;D</b>	Comer Commons
12/8/15	<b>Donald Durden, MD, PhD</b>	UCSD	<b>Rational <i>in silico</i> design of dual inhibitory chemotypes for cancer therapeutics; Bench to bedside</b>	Comer Commons
12/15/15	<b>Razelle Kurzrock, MD</b>	Moores UCSD Cancer Center	<b>Drug development in the genomic era</b>	Comer Commons
1/5/16	<b>Olivier Harismendy, PhD</b>	Moores UCSD Cancer Center	<b>Cancer Genomic Data and Resources for Target Discovery</b>	Comer Commons
1/19/16	<b>Peter Worland</b>	Celgene	<b>Drug Discovery Not Discussed</b>	Comer Commons
1/26/16	<b>Scott Weinrich Jennifer LaFontaine</b>	Pfizer	<b>Drug discovery: Chemistry and Biology</b>	Comer Commons
2/9/16	<b>Silvio Gutkind, PhD</b>	Moores UCSD Cancer Center	<b>Targeting the mTOR Signaling Circuitry for Cancer Prevention and Treatment: A Bridge from Bench to Clinic</b>	Comer Commons
2/16/16	<b>Deepak Dalvie, PhD</b>	Pfizer	<b>Pharmacokinetics and metabolism</b>	Comer Commons
2/23/16	<b>Ezra Cohen, MD</b>	Moores UCSD Cancer Center	<b>Phenotypes, Prognostics, and Precision in Head and Neck Squamous Cell Carcinoma</b>	Comer Commons
3/1/16	<b>Charles Theuer, MD, PhD</b>	Tracon Pharmaceuticals	<b>Can the next generation of angiogenesis inhibitors be more successful than the first generation of angiogenesis inhibitors?</b>	Comer Commons
3/8/16	<b>Robert Hershberg, MD, PhD</b>	CEO, VentiRx CSO, Celgene	<b>Not Just Another Checkpoint Inhibitor-- Development of Novel Toll-like Receptor 8 (TLR8) Agonists in Cancer</b>	Comer Commons
3/22/16	<b>Greg Stevens/Laurie Strawn</b>	Pfizer	<b>Drug safety and regulatory</b>	Comer Commons
3/29/16	<b>Dan Shoemaker</b>	Fate Therapeutics	<b>Using Small Molecules to Generate Programmed Cellular Immunotherapies for Fighting Cancer</b>	Comer Commons
4/5/16	<b>Hakan Sakul</b>	Pfizer	<b>Precision Medicine and diagnostics</b>	Comer Commons

**The CANCER THERAPEUTICS TRAINING PROGRAM LECTURE SERIES (CHEM239) 2015 – 2016**  
*Tuesdays 12:00 to 1:00 PM      Lunch is available at 11:45 AM for those attending the lecture*

<b>Date</b>	<b>Speaker</b>	<b>Affiliation</b>	<b>Title</b>	<b>Location</b>
4/12/16	<b>Liangfang Zhang, PhD</b>	Moore's UCSD Cancer Center	<b>Biomimetic Nanoparticles for Anticancer Drug Delivery and Vaccination</b>	Comer Commons
5/3/16	<b>Jon Cheng</b>	<b>Merck</b>	<b>Pembrolizumab: Harnessing the power of the immune system to fight cancer</b>	Comer Commons
5/10/16	<b>Diane Boucher, MD</b>	<b>Vertex</b>	<b>Discovery of a Selective DNA-PK Inhibitor for the Treatment of Cancer</b>	Comer Commons
5/17/16	<b>Eric Murphy, PhD</b>	<b>Crown Bioscience</b>	<b>SCLC PDX Trials: From PARP Inhibitor Combination Therapy to anti-PD-1</b>	Comer Commons
5/24/16	<b>Dan Gold</b>	MeiPharma	<b>Cancer Drug Development: Know your Target Patient Population, the Sooner the Better</b>	Comer Commons
5/31/16	<b>Tom Bumol</b>	<b>Lilly</b>	<b>Biological Therapies For Cancer Treatment: Some "Personal" Reflections</b>	Comer Commons